Review Note
Last Update: 03/26/2024 06:17 AM
Current Deck: Spring 2024 P1 Semester::Pharm 232 (new)::Exam 2
PublishedCurrently Published Content
Text
ANTIRHEUMATIC DRUG THERAPY-MONITORING
{{c1::Methotrexate}} (antimetabolite, chemotherapeutic agent)
• CBC w/diff, Plt, AST/ALP, Bili, Albumin, s/s infection.
• ADRs: leukopenia, pancytopenia, Hepatotox, infection.
{{c1::Prednisone}}
• CBC w/diff, Plt, Gluc, ‘lytes, Lipids
• ADRs: Anemia 20 to GI bleed, Hyperglycemia,
{{c1::NSAIDs}}
• CBC w/diff, AST/ALT, BUN, Cr, UA
• ADRs: Anemia 20 to GI bleed, Kidney dysfunction, hepatotox,
{{c1::Cyclosporine}}
• BUN, Cr, Blood levels, Electrolytes (K+), Uric Acid, AST/ALT, Bili
• ADRs: Nephrotoxicity, Hyper K, Hyperuricemia, Hepatotoxicity
{{c1::Methotrexate}} (antimetabolite, chemotherapeutic agent)
• CBC w/diff, Plt, AST/ALP, Bili, Albumin, s/s infection.
• ADRs: leukopenia, pancytopenia, Hepatotox, infection.
{{c1::Prednisone}}
• CBC w/diff, Plt, Gluc, ‘lytes, Lipids
• ADRs: Anemia 20 to GI bleed, Hyperglycemia,
{{c1::NSAIDs}}
• CBC w/diff, AST/ALT, BUN, Cr, UA
• ADRs: Anemia 20 to GI bleed, Kidney dysfunction, hepatotox,
{{c1::Cyclosporine}}
• BUN, Cr, Blood levels, Electrolytes (K+), Uric Acid, AST/ALT, Bili
• ADRs: Nephrotoxicity, Hyper K, Hyperuricemia, Hepatotoxicity
Back Extra
Current Tags:
Pending Suggestions
No pending suggestions for this note.